DK0828494T3 - Fremgangsmåde til behandling af kognitiv dysfunktion - Google Patents

Fremgangsmåde til behandling af kognitiv dysfunktion

Info

Publication number
DK0828494T3
DK0828494T3 DK95922148T DK95922148T DK0828494T3 DK 0828494 T3 DK0828494 T3 DK 0828494T3 DK 95922148 T DK95922148 T DK 95922148T DK 95922148 T DK95922148 T DK 95922148T DK 0828494 T3 DK0828494 T3 DK 0828494T3
Authority
DK
Denmark
Prior art keywords
cognitive dysfunction
treatment
methyl
benzodiazepine
thieno
Prior art date
Application number
DK95922148T
Other languages
English (en)
Inventor
Charles M Beasley Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from CA002219902A external-priority patent/CA2219902A1/en
Application granted granted Critical
Publication of DK0828494T3 publication Critical patent/DK0828494T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Processing Of Meat And Fish (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Light Receiving Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DK95922148T 1995-05-30 1995-05-30 Fremgangsmåde til behandling af kognitiv dysfunktion DK0828494T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002219902A CA2219902A1 (en) 1995-05-30 1995-05-30 Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction
PCT/US1995/006859 WO1996038151A1 (en) 1995-05-30 1995-05-30 Method for treating cognitive dysfunction

Publications (1)

Publication Number Publication Date
DK0828494T3 true DK0828494T3 (da) 2002-09-02

Family

ID=25679786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95922148T DK0828494T3 (da) 1995-05-30 1995-05-30 Fremgangsmåde til behandling af kognitiv dysfunktion

Country Status (17)

Country Link
EP (1) EP0828494B1 (da)
JP (1) JPH11506096A (da)
AT (1) ATE220550T1 (da)
AU (1) AU707858B2 (da)
CZ (1) CZ292565B6 (da)
DE (1) DE69527442T2 (da)
DK (1) DK0828494T3 (da)
ES (1) ES2180643T3 (da)
FI (1) FI973987A (da)
HK (1) HK1009393A1 (da)
HU (1) HUT77907A (da)
MX (1) MX9707936A (da)
NO (1) NO318553B1 (da)
NZ (1) NZ288037A (da)
PL (1) PL189714B1 (da)
PT (1) PT828494E (da)
WO (1) WO1996038151A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU707858B2 (en) 1999-07-22
DE69527442D1 (de) 2002-08-22
DE69527442T2 (de) 2003-02-20
EP0828494A4 (en) 1999-11-24
MX9707936A (es) 1997-12-31
PL189714B1 (pl) 2005-09-30
HUT77907A (hu) 1998-10-28
EP0828494A1 (en) 1998-03-18
NO318553B1 (no) 2005-04-11
ES2180643T3 (es) 2003-02-16
FI973987A0 (fi) 1997-10-17
WO1996038151A1 (en) 1996-12-05
FI973987A (fi) 1997-10-17
PT828494E (pt) 2002-10-31
NO974766D0 (no) 1997-10-15
AU2693695A (en) 1996-12-18
JPH11506096A (ja) 1999-06-02
NZ288037A (en) 1999-09-29
HK1009393A1 (en) 1999-06-04
NO974766L (no) 1997-12-09
ATE220550T1 (de) 2002-08-15
CZ324397A3 (cs) 1998-08-12
EP0828494B1 (en) 2002-07-17
PL323785A1 (en) 1998-04-27
CZ292565B6 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
MY114701A (en) Process and crystal forms of 2-methyl-thieno- benzodiazepine
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
ATE500258T1 (de) Verfahren zur herstellung von olanzapin form i
AR002336A1 (es) Proceso para el tratamiento de gas efluente
ZA963098B (en) Method for treating dyskinesias.
NZ510208A (en) Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt
ZA971566B (en) Method of treating leather with pmphoteric polymers.
DK0828494T3 (da) Fremgangsmåde til behandling af kognitiv dysfunktion
NZ332037A (en) Olanzapine for treating migraine pain
TW429149B (en) Pharmaceutical composition for treating conditions resulting from the cessation and withdrawal from the use of nicotine
DK0773192T3 (da) Fremgangsmåde til behandling af selenholdigt spildevand
ZA976854B (en) Treatment of psychotic disorders.
DK0831835T3 (da) Behandling af anorexia
DK0877818T3 (da) Fremgangsmåde til aktivering af en kinase
HUP9902882A2 (hu) Olanzapin alkalmazása álmatlanság kezelésére szolgáló gyógyszerkészítmények előállítására
NZ331846A (en) Method for preparing a medicament using olanzapine for treating insomnia
ZA966936B (en) Process for the treatment of water.
ES1033530Y (es) Aparato para depurar aguas residuales.
ZA966815B (en) Method of treating water.
ZA963472B (en) Method of treatment.
ZA991836B (en) Method of treating sewage.